Current Problems in Cardiology
Volume 31, Issue 12 , Pages 769-817 , December 2006

Modern Management of Acute Myocardial Infarction

References 

  1. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44:1–211
  2. McGovern PG, Pankow JS, Shahar E, et al. Recent trends in acute coronary heart disease—mortality, morbidity, medical care, and risk factors (The Minnesota Heart Survey Investigators). N Engl J Med. 1996;334:884–890
  3. Roger VL, Jacobsen SJ, Weston SA, et al. Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. Ann Intern Med. 2002;136:341–348
  4. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897–902
  5. DeWood MA, Stifter WF, Simpson CS, et al. Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med. 1986;315:417–423
  6. Yamaji H, Iwasaki K, Kusachi S, et al. Prediction of acute left main coronary artery obstruction by 12-lead electrocardiography (ST segment elevation in lead aVR with less ST segment elevation in lead V(1)). J Am Coll Cardiol. 2001;38:1348–1354
  7. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959–969
  8. Adams JE, Sicard GA, Allen BT, et al. Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I. N Engl J Med. 1994;330:670–674
  9. Galvani M, Ottani F, Ferrini D, et al. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. Circulation. 1997;95:2053–2059
  10. Newby LK, Christenson RH, Ohman EM, et al. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes (The GUSTO-IIa Investigators). Circulation. 1998;98:1853–1859
  11. Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia (GUSTO IIA Investigators). N Engl J Med. 1996;335:1333–1341
  12. Hamm CW, Ravkilde J, Gerhardt W, et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med. 1992;327:146–150
  13. Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during InStability in Coronary artery disease. Lancet. 2000;356:9–16
  14. Wu AH, Apple FS, Gibler WB, et al. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem. 1999;45:1104–1121
  15. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit (A two year experience with 250 patients). Am J Cardiol. 1967;20:457–464
  16. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349–360
  17. Lau J, Antman EM, Jimenez-Silva J, et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327:248–254
  18. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730–1737
  19. Roberts R, Rogers W, Mueller H, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction (Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study). Circulation. 1991;83:422–437
  20. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group (Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial). Lancet. 2005;366:1622–1632
  21. Faxon DP. Beta-blocker therapy and primary angioplasty: what is the controversy?. J Am Coll Cardiol. 2004;43:1788–1790
  22. Jugdutt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications (Effect of timing, dosage, and infarct location). Circulation. 1988;78:906–919
  23. Jugdutt BI, Becker LC, Hutchins GM, et al. Effect of intravenous nitroglycerin on collateral blood flow and infarct size in the conscious dog. Circulation. 1981;63:17–28
  24. Antman EM, Morrow DA, McCabe CH, et al. ExTRACT-TIMI 25 Investigators Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction (doi;10.1056/NEJMoa060898). N Engl J Med. 2006;354:1477–1488
  25. Van de Werf FJ, Armstrong PW, Granger C, et al. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605–613
  26. Van de Werf F, Baim DS. Reperfusion for ST-segment elevation myocardial infarction: an overview of current treatment options. Circulation. 2002;105:2813–2816
  27. Ribichini F, Wijns W. Acute myocardial infarction: reperfusion treatment. Heart. 2002;88:298–305
  28. Gersh BJ, Stone GW, White HD, et al. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?. JAMA. 2005;293:979–986
  29. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118–1123
  30. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial (Assessment of the Safety and Efficacy of a New Thrombolytic Investigators). Lancet. 1999;354:716–722
  31. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13–20
  32. De Luca G, Suryapranata H, Ottervanger JP, et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. 2004;109:1223–1225
  33. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything?. Am J Cardiol. 2003;92:824–826
  34. Kastrati A, Mehilli J, Schlotterbeck K, et al. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled Trial. JAMA. 2004;291:947–954
  35. Van de Werf F. ASSENT 4, European Society of Cardiology Congress, Stockholm, Sweden, 2005.
  36. Le May MR, Wells GA, Labinaz M, et al. Combined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI Study). J Am Coll Cardiol. 2005;46:417–424
  37. Gershlick AH, Stephens-Lloyd A, Hughes S, et al. REACT Trial Investigators Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction (doi;10.1056/NEJMoa050849). N Engl J Med. 2005;353:2758–2768
  38. Fernandez-Aviles PF, Alonso PJJ, Castro-Beiras PA, et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet. 2004;364:1045–1053
  39. Quinn MJ, Fitzgerald DJ. Ticlopidine and Clopidogrel. Circulation. 1999;100:1667–1672
  40. Sabatine MS, Cannon CP, Gibson CM, et al. CLARITY-TIMI 28 Investigators Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179–1189
  41. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–533
  42. Weitz J, Califf R, Ginsberg J, et al. New antithrombotics. Chest. 1995;108:471S–485S
  43. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;332:349–360
  44. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation. 1999;99:2720–2732
  45. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation. 2000;101:2788–2794
  46. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet. 2001;357:1905–1914
  47. Giugliano RP, Roe MT, Harrington RA, et al. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic trial. J Am Coll Cardiol. 2003;41:1251–1260
  48. Zorman S, Zorman D Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol. 2002;90:533–536
  49. Arntz H-R, Schroder J, Pels K. Prehospital versus periprocedural administration of abciximab in STEMI: early and late results from the randomised REOMOBILE-study. Eur Heart J. 2003;24:268
  50. Mesquita Gabriel H, Oliveira J, Canas da Silva P, et al. Early administration of abciximab bolus in the emergency room improves microperfusion after primary percutaneous coronary intervention, as assessed by TIMI frame count: results of the ERAMI trial. Eur Heart J. 2003;24:543
  51. Lee DP, Herity NA, Hiatt BL, et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial. Circulation. 2003;107:1497-1.
  52. Cutlip DE, Ricciardi MJ, Ling FS, et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol. 2003;92:977–980
  53. van’t Hof AWJ, Ernst N, de Boer M-J, et al. on behalf of the On-TIME study group (Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial). Eur Heart J. 2004;25:837–846
  54. Cutlip DE, Cove CJ, Irons D, et al. Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarction and its effect on baseline coronary flow and procedure outcomes. Am J Cardiol. 2001;88:62–64
  55. Zeymer U, Zahn R, Schiele R, et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J. 2005;ehi293
  56. Montalescot G, Borentain M, Payot L, et al. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2004;292:362–366
  57. Mehta RH, Harjai KJ, Cox D, et al. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1739–1746
  58. Kenner MD, Zajac EJ, Kondos GT, et al. Ability of the no-reflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one-month follow-up. Am J Cardiol. 1995;76:861–868
  59. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the ‘no reflow’ phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93:223–228
  60. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366–1374
  61. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction (Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)). N Engl J Med. 1992;327:678–684
  62. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction (Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico). Lancet. 1994;343:1115–1122
  63. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669–685
  64. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet. 1995;345:686–687
  65. Pfeffer MA, Braunwald E, Moye LA, et al. The SAVE Investigators Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction (Results of the survival and ventricular enlargement trial). N Engl J Med. 1992;327:669–677
  66. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction (Trandolapril Cardiac Evaluation (TRACE) Study Group). N Engl J Med. 1995;333:1670–1676
  67. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821–828
  68. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction (The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators). N Engl J Med. 1995;332:80–85
  69. Kingma JH, van Gilst WH, Peels CH, et al. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction (Results from the Captopril and Thrombolysis Study (CATS)). Eur Heart J. 1994;15:898–907
  70. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–2346
  71. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005;46:1425–1433
  72. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both (doi;10.1056/NEJMoa032292). N Engl J Med. 2003;349:1893–1906
  73. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction (doi;10.1056/NEJMoa030207). N Engl J Med. 2003;348:1309–1321
  74. Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. doi;10.1001/jama.284.7.835. JAMA. 2000;284:835–842
  75. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet. 1996;347:561–568
  76. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events). J Am Coll Cardiol. 2000;36:693–698
  77. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction (TIMI 11B-ESSENCE meta-analysis). Circulation. 1999;100:1602–1608
  78. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:701–707
  79. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J. 1999;20:1553–1562
  80. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes (doi;10.1056/NEJMoa055443). N Engl J Med. 2006;354:1464–1476
  81. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498–1505
  82. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488–1497
  83. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med. 1998;339:436–443
  84. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation. 2002;105:316–321
  85. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a global organization network. Circulation. 1998;97:2386–2395
  86. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357:1915–1924
  87. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-2.
  88. Hongo RH, Ley J, Dick SE, et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol. 2002;40:231–237
  89. Kastrati A, Mehilli J, Neumann F-J, et al. Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 Randomized Trial (doi;10.1001/jama.295.13.joc60034). JAMA. 2006;295:1531–1538
  90. McCullough PA, O’Neill WW, Graham M, et al. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy (Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial). J Am Coll Cardiol. 1998;32:596–605
  91. Boden WE, O’Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy (Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators). N Engl J Med. 1998;338:1785–1792
  92. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study (FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators). Lancet. 1999;354:708–715
  93. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879–1887
  94. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial (Randomized Intervention Trial of unstable Angina). Lancet. 2002;360:743–751
  95. de Winter RJ, Windhausen F, Cornel JH, et al. Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators Early invasive versus selectively invasive management for acute coronary syndromes (doi;10.1056/NEJMoa044259). N Engl J Med. 2005;353:1095–1104
  96. Nishimura RA, Schaff HV, Gersh BJ, et al. Early repair of mechanical complications after acute myocardial infarction. JAMA. 1986;256:47–50
  97. Nishimura RA, Schaff HV, Shub C, et al. Papillary muscle rupture complicating acute myocardial infarction: analysis of 17 patients. Am J Cardiol. 1983;51:373–377
  98. Chen Q, Darlymple-Hay MJ, Alexiou C, et al. Mitral valve surgery for acute papillary muscle rupture following myocardial infarction. J Heart Valve Dis. 2002;11:27–31
  99. Honan MB, Harrell FE, Reimer KA, et al. Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Cardiol. 1990;16:359–367
  100. Kinn JW, O’Neill WW, Benzuly KH, et al. Primary angioplasty reduces risk of myocardial rupture compared to thrombolysis for acute myocardial infarction. Cathet Cardiovasc Diagn. 1997;42:151–157
  101. Becker RC, Gore JM, Lambrew C, et al. A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction. J Am Coll Cardiol. 1996;27:1321–1326
  102. Purcaro A, Costantini C, Ciampani N, et al. Diagnostic criteria and management of subacute ventricular free wall rupture complicating acute myocardial infarction. Am J Cardiol. 1997;80:397–405
  103. Becker RC, Hochman JS, Cannon CP, et al. Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists—observations from the thrombolysis and thrombin inhibition in myocardial infarction 9 study. J Am Coll Cardiol. 1999;33:479–487
  104. Solodky A, Behar S, Herz I, et al. Comparison of incidence of cardiac rupture among patients with acute myocardial infarction treated by thrombolysis versus percutaneous transluminal coronary angioplasty. Am J Cardiol. 2001;87:1105–1108
  105. Moreno R, Lopez-Sendon J, Garcia E, et al. Primary angioplasty reduces the risk of left ventricular free wall rupture compared with thrombolysis in patients with acute myocardial infarction. J Am Coll Cardiol. 2002;39:598–603
  106. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA. 2001;285:190–192
  107. Slater J, Brown RJ, Antonelli TA, et al. Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry. J Am Coll Cardiol. 2000;36:1117–1122
  108. Lopez-Sendon J, Gonzalez A, Lopez de Sa E, et al. Diagnosis of subacute ventricular wall rupture after acute myocardial infarction: sensitivity and specificity of clinical, hemodynamic and echocardiographic criteria. J Am Coll Cardiol. 1992;19:1145–1153
  109. Montoya A, McKeever L, Scanlon P, et al. Early repair of ventricular septal rupture after infarction. Am J Cardiol. 1980;45:345–348
  110. Scanlon PJ, Montoya A, Johnson SA, et al. Urgent surgery for ventricular septal rupture complicating acute myocardial infarction. Circulation. 1985;72:II185–90
  111. Padro JM, Caralps JM, Montoya JD, et al. Sutureless repair of postinfarction cardiac rupture. J Card Surg. 1988;3:491–493
  112. Lachapelle K, deVarennes B, Ergina PL, et al. Sutureless patch technique for postinfarction left ventricular rupture. Ann Thorac Surg. 2002;74:96–101
  113. Frances C, Romero A, Grady D. Left ventricular pseudoaneurysm. J Am Coll Cardiol. 1998;32:557–561
  114. Yeo TC, Malouf JF, Reeder GS, et al. Clinical characteristics and outcome in postinfarction pseudoaneurysm. Am J Cardiol. 1999;84:592–595A8
  115. Birnbaum Y, Wagner GS, Gates KB, et al. Clinical and electrocardiographic variables associated with increased risk of ventricular septal defect in acute anterior myocardial infarction. Am J Cardiol. 2000;86:830–834
  116. Lemery R, Smith HC, Giuliani ER, et al. Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early surgical intervention. Am J Cardiol. 1992;70:147–151
  117. Crenshaw BS, Granger CB, Birnbaum Y, et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. Circulation. 2000;101:27–32
  118. Labrousse L, Choukroun E, Chevalier JM, et al. Surgery for post infarction ventricular septal defect (VSD): risk factors for hospital death and long term results. Eur J Cardiothorac Surg. 2002;21:725–732
  119. Landzberg MJ, Lock JE. Transcatheter management of ventricular septal rupture after myocardial infarction. Semin Thorac Cardiovasc Surg. 1998;10:128–132
  120. Archbold RA, Sayer JW, Ray S, et al. Frequency and prognostic implications of conduction defects in acute myocardial infarction since the introduction of thrombolytic therapy. Eur Heart J. 1998;19:893–898
  121. Rathore SS, Gersh BJ, Berger PB, et al. Acute myocardial infarction complicated by heart block in the elderly: prevalence and outcomes. Am Heart J. 2001;141:47–54
  122. Harpaz D, Behar S, Gottlieb S, et al. Complete atrioventricular block complicating acute myocardial infarction in the thrombolytic era. J Am Coll Cardiol. 1999;34:1721–1728
  123. Berger PB, Ruocco NA, Ryan TJ, et al. Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II. J Am Coll Cardiol. 1992;20:533–540
  124. Goodfellow J, Walker PR. Reversal of atropine-resistant atrioventricular block with intravenous aminophylline in the early phase of inferior wall acute myocardial infarction following treatment with streptokinase. Eur Heart J. 1995;16:862–865
  125. Woods KL, Fletcher S, Roffe C, et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet. 1992;339:1553–1558
  126. Go AS, Barron HV, Rundle AC, et al. Bundle-branch block and in-hospital mortality in acute myocardial infarction (National Registry of Myocardial Infarction 2 Investigators). Ann Intern Med. 1998;129:690–697
  127. Brilakis ES, Wright RS, Kopecky SL, et al. Bundle branch block as a predictor of long-term survival after acute myocardial infarction. Am J Cardiol. 2001;88:205–209
  128. Crenshaw BS, Ward SR, Granger CB, et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol. 1997;30:406–413
  129. Pedersen OD, Bagger H, Kober L, et al. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. Eur Heart J. 1999;20:748–754
  130. Rathore SS, Berger AK, Weinfurt KP, et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly—prevalence and outcomes. Circulation. 2000;101:969–974
  131. Al-Khatib SM, Pieper KS, Lee KL, et al. Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial. Am J Cardiol. 2001;88:76–79
  132. Goldberg RJ, Yarzebski J, Lessard D, et al. Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective. Am Heart J. 2002;143:519–527
  133. Widimsky P, Budesinsky T, Vorac D, et al. ‘PRAGUE’ Study Group Investigators Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: final results of the randomized national multicentre trial—PRAGUE-2. Eur Heart J. 2003;24:94–4
  134. Grines CL, Westerhausen J, Donald R, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the air primary angioplasty in myocardial infarction study. J Am Coll Cardiol. 2002;39:1713–1719
  135. Andersen HR, Nielsen TT, Rasmussen K, et al. DANAMI-2 Investigators A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349:733–742
  136. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease (Fragmin in unstable coronary artery disease study (FRIC)). Circulation. 1997;96:61–68
  137. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group). N Engl J Med. 1997;337:447–452
  138. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction (Results of the thrombolysis in myocardial infarction (TIMI) 11B trial). Circulation. 1999;100:1593–1601
  139. Verheugt FW. Acute coronary syndromes: drug treatments. Lancet. 1999;353:SII20–3

 The authors have no conflicts of interest to disclose.

PII: S0146-2806(06)00115-0

doi: 10.1016/j.cpcardiol.2006.08.004

Current Problems in Cardiology
Volume 31, Issue 12 , Pages 769-817 , December 2006

Article Tools

* Image Usage & Resolution